Log In
Print this Print this

linagliptin/metformin extended release (Jentadueto XR)

  Manage Alerts
Collapse Summary General Information
Company Boehringer Ingelheim GmbH
DescriptionExtended-release combination of Tradjenta linagliptin, a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26)
Mechanism of ActionDipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentApproved
Standard IndicationDiabetes
Indication DetailsAdjunct to diet and exercise to improve glycemic control in adults with Type II diabetes when treatment with both linagliptin and metformin is appropriate
Regulatory Designation
PartnerEli Lilly and Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today